Cargando…
Interim results of a clinical trial using oncolytic virotherapy in Kaposi's sarcoma-associated herpesvirus (KSHV) associated-Multicentric Castleman's Disease (MCD)
Autores principales: | Yarchoan, R, O'Mahony, D, Aleman, K, Wyvill, KM, Whitby, D, Bernstein, W, Pittaluga, S, Jaffe, ES, Tosato, G, Davis, DA, Steinberg, SM, Little, RF |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261728/ http://dx.doi.org/10.1186/1750-9378-4-S2-O20 |
Ejemplares similares
-
Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi sarcoma-associated herpes virus (KSHV) associated multicentric Castleman disease (MCD)
por: Uldrick, Thomas, et al.
Publicado: (2010) -
KSHV activation, human and viral IL-6 production, and other cytokine dysregulation: Association with the symptomatology of KSHV-associated multicentric Castleman’s disease
por: Polizzotto, Mark N, et al.
Publicado: (2010) -
Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV–MCD) and the KSHV Inflammatory Cytokine Syndrome
por: Polizzotto, Mark N., et al.
Publicado: (2012) -
Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome
por: Polizzotto, Mark N., et al.
Publicado: (2017) -
Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are associated with markedly elevated serum IL-10, elevated IL-6, IL-17 and circulating KSHV
por: Uldrick, Thomas S, et al.
Publicado: (2012)